Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 29, 2018. The report disseminates an LSE Announcement regarding ViiV Healthcare, a global specialist HIV company established by GSK, Pfizer, and Shionogi. The filing focuses on clinical trial results rather than corporate financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a clinical update and does not contain financial statements or key performance indicators for GSK or ViiV Healthcare.
Material Changes and Clinical Results
The primary material update concerns the LATTE-2 Phase IIb study of a long-acting, injectable, two-drug HIV regimen (cabotegravir and rilpivirine). Key results at 160 weeks include:
- Virologic Response: 90% (104/115) of patients on the every-eight-week dosing schedule and 83% (95/115) on the every-four-week schedule remained virally suppressed.
- Switching from Oral Regimen: Among patients who switched from an oral comparator to the injectable regimen at Week 96, 97% (33/34) and 100% (10/10) remained suppressed on the eight-week and four-week schedules, respectively, at Week 160.
- Resistance: Two patients developed protocol-defined virologic failure on the eight-week arm through Week 48; no additional cases were observed between Week 48 and Week 160.
- Tolerability: A majority of participants reported injection site reactions (ISRs), 85% of which were mild and 14% moderate. 87% of ISRs resolved within seven days. Only 3/274 patients discontinued due to ISRs.
Outlook, Risks, and Management Commentary
Management Commentary: John C. Pottage, Jr., MD, Chief Scientific and Medical Officer at ViiV Healthcare, stated that the long-term data supports the regimen as an alternative to daily pills, potentially reducing annual doses from 365 to 12. The results demonstrate high rates of virologic response and long-term durability.
Future Pipeline: The regimen is currently being investigated in three Phase III studies: FLAIR, ATLAS, and ATLAS-2M. These studies evaluate safety and efficacy in patients suppressed on various oral regimens.
Risks and Contingencies:
- Safety Warnings: The filing includes standard safety information for rilpivirine (Edurant), noting risks of severe skin/hypersensitivity reactions, hepatotoxicity, depressive disorders, and immune reconstitution syndrome.
- Drug Interactions: Contraindications exist with drugs that induce CYP3A enzymes or increase gastric pH (e.g., rifampin, proton pump inhibitors).
- Forward-Looking Statements: GSK cautions that projections are subject to risks and uncertainties that may cause actual results to differ materially.
Investor Verification Checklist
- Verify the enrollment and primary endpoints of the ongoing Phase III studies (FLAIR, ATLAS, ATLAS-2M).
- Confirm the regulatory status of cabotegravir, which remains investigational and is not approved by any regulatory authority.
- Review the full prescribing information for rilpivirine to understand specific contraindications and adverse event profiles.
- Monitor upcoming data releases from the Phase III trials to assess commercial viability and potential approval timelines.